Loading...
XKRX214150
Market cap2.20bUSD
Dec 24, Last price  
49,500.00KRW
1D
1.33%
1Q
-7.48%
IPO
972.59%
Name

Classys Inc

Chart & Performance

D1W1MN
XKRX:214150 chart
P/E
42.95
P/S
17.70
EPS
1,152.40
Div Yield, %
0.23%
Shrs. gr., 5y
Rev. gr., 5y
32.51%
Revenues
180.12b
+27.02%
81,133,256,55076,460,931,510100,596,935,570141,803,242,400180,122,798,010
Net income
74.23b
-1.53%
33,393,938,58938,164,823,42043,804,676,38075,378,647,24074,225,203,050
CFO
64.63b
+18.04%
39,033,739,58038,125,167,92036,367,042,25054,754,505,36064,631,971,910
Dividend
Dec 27, 2023116 KRW/sh
Earnings
Mar 18, 2025

Profile

CLASSYS Inc. provides medical aesthetics devices worldwide. Its products include SCIZER for non-invasive subcutaneous fat reduction; ULTRAFORMER MPT, a solution for eyebrow lifting by coagulating skin tissue with a focused ultrasound stimulation system; ULTRAFORMER III, a high-intensity focused ultrasound surgical device used for tissue coagulation in eyelid lifting for skin tightening and improving subcutaneous tissue elasticity in the face (cheeks), abdomen, and thighs, as well as for addressing crow's feet, laugh lines, and neck wrinkles; INTRASURE, an aesthetics and healthcare multi-platform solution; FORSHAPE, an RF treatment system to increase metabolism, blood circulation, and tissue recovery; and VOLNEWMER, a monopolar radiofrequency therapeutic equipment used to coagulate skin tissue as a general electrosurgical instrument. It also provides CLATUU Alpha, a medical device that gradually reduces subcutaneous fat layers, particularly in areas with excessive fat accumulation, using low-temperature energy and negative pressure; Ulfit, a medical device used to improve skin elasticity and subcutaneous tissue in the abdomen and thighs by delivering HIFU energy; Refit, a medical device that uses RF and negative pressure to increase tissue temperature and blood flow, relieving pain in the treated area; AQUAPURE is the combination of four handpieces are respectively applied for acne suction, muscle pain relief, and other pain relief; and AQUAPURE II, a multi-functional facial and body care device. The company offers its products under the Classys, Cluederm, and the SKEDERM brands. It serves clinics, hospitals, and beauty salons. The company was incorporated in 2007 and is headquartered in Seoul, South Korea.
IPO date
Apr 03, 2015
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑12
Income
Revenues
180,122,798
27.02%
141,803,242
40.96%
100,596,936
31.57%
Cost of revenue
74,054,264
58,265,403
36,718,742
Unusual Expense (Income)
NOPBT
106,068,534
83,537,840
63,878,194
NOPBT Margin
58.89%
58.91%
63.50%
Operating Taxes
19,616,641
21,379,789
11,819,912
Tax Rate
18.49%
25.59%
18.50%
NOPAT
86,451,893
62,158,050
52,058,282
Net income
74,225,203
-1.53%
75,378,647
72.08%
43,804,676
14.78%
Dividends
(7,471,452)
(4,271,313)
(3,882,550)
Dividend yield
0.31%
0.36%
0.32%
Proceeds from repurchase of equity
(14,578,009)
(5,313,131)
13,999
BB yield
0.60%
0.45%
0.00%
Debt
Debt current
3,139,369
2,957,303
514,155
Long-term debt
63,716,796
66,039,931
36,097,055
Deferred revenue
207,422
690,712
178,000
Other long-term liabilities
10
(170)
Net debt
44,312,305
41,623,090
(8,368,691)
Cash flow
Cash from operating activities
64,631,972
54,754,505
36,367,042
CAPEX
(6,112,522)
(27,998,696)
(33,037,660)
Cash from investing activities
(48,157,758)
(91,994,853)
(92,466,135)
Cash from financing activities
(25,643,962)
21,055,239
30,719,729
FCF
20,162,199
45,123,787
13,665,752
Balance
Cash
137,837,865
113,223,567
48,771,336
Long term investments
(115,294,004)
(85,849,422)
(3,791,435)
Excess cash
13,537,721
20,283,982
39,950,054
Stockholders' equity
279,270,730
210,746,078
139,622,327
Invested Capital
335,798,284
258,725,300
153,812,329
ROIC
29.08%
30.13%
49.31%
ROCE
30.36%
29.94%
32.90%
EV
Common stock shares outstanding
64,405
64,703
64,800
Price
37,750.00
105.16%
18,400.00
-2.13%
18,800.00
22.08%
Market cap
2,431,290,713
104.22%
1,190,529,698
-2.27%
1,218,236,560
22.09%
EV
2,475,603,018
1,232,152,788
1,209,867,869
EBITDA
110,346,173
87,437,535
66,401,209
EV/EBITDA
22.43
14.09
18.22
Interest
1,958,684
2,609,848
93,054
Interest/NOPBT
1.85%
3.12%
0.15%